Compare RGNX & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNX | FEIM |
|---|---|---|
| Founded | 2008 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 439.6M |
| IPO Year | 2015 | 1994 |
| Metric | RGNX | FEIM |
|---|---|---|
| Price | $8.76 | $51.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $28.75 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 501.7K | 165.5K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.08 | ★ 316.95 |
| EPS | N/A | ★ 0.41 |
| Revenue | $10,393,000.00 | ★ $69,811,000.00 |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | $21.73 |
| P/E Ratio | ★ N/A | $126.63 |
| Revenue Growth | ★ 126.48 | 26.30 |
| 52 Week Low | $6.89 | $16.69 |
| 52 Week High | $16.19 | $61.47 |
| Indicator | RGNX | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 47.63 |
| Support Level | $8.68 | $49.46 |
| Resistance Level | $9.29 | $59.75 |
| Average True Range (ATR) | 0.48 | 3.83 |
| MACD | 0.02 | -0.39 |
| Stochastic Oscillator | 28.57 | 12.41 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.